Autopsy report · NCT04920968

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Following the recommendation of the Data Monitoring Committee (DMC), based on the results of the interim analysis, the Sponsor has decided to terminate the study prematurely”

The sponsor’s own words in the registry.

Life of this trial

Registered 5 months before it started.
Ran for about 4 years 7 months before it stopped.
49 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology
Sponsor type: University, hospital or other
Conditions: CD20-positive Acute Lymphoblastic Leukemia
Interventions: Obinutuzumab; Rituximab
Participants: 49
Sites: 19
Countries: Poland

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.